Hold EMR at Neutral Weight with $144 Stop and Executable Pre-Committed Triggers
Hold EMR at neutral weight with $144 stop loss, $163-167 target, and pre-committed executable triggers. The structural floor ($2.4B annual capital return, 67-year dividend streak, golden cross, $3.71B TTM FCF) has absorbed dense bearish convergence three consecutive times at comparable price zones. The 8/25 meta-lesson explicitly requires fresh evidence—not pattern-matching to the dense-bearish-convergence checklist—before deviating from Hold. Reject aggressive trim (25-40%), conservative trim (10-20% with too-tight stop), and trader Sell (incoherent $170 stop above entry). Hold the name with disciplined triggers; the Q4 FY26 print is the validating catalyst.
| Position | Action |
|---|---|
| Default | Maintain current position; no add, no preemptive trim |
| Close < $148 on volume > 2.5M with MACD confirmation, OR EPS revisions toward $6.50-6.75, OR hawkish FOMC surprise | Trim 25% (downgrade to Underweight) |
| Close > $166.65 on volume > 3.5M with MACD expansion AND EPS revisions toward $7.50+ | Upgrade to Overweight |
| Pullback to $144-$148 zone with bullish reversal candle on declining volume AND RSI reset 45-50 AND MACD histogram contraction | Add on basing |
| Rally to $164-$170 without volume confirmation (< 3.5M shares, MACD histogram contracting) | Trim into strength |
EMR is a quality compounder in the middle of a multi-year software-tilted transformation, with accelerating revenue visibility, best-in-class margins, fortress balance sheet, and AI/data-center tailwinds that the market is still mispricing due to near-term fear.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | 157.62 | neutral |
| close_50_sma | 148.29 | bullish |
| close_200_sma | 140.90 | bullish |
| rsi | 56.39 | neutral |
| macd | 2.80 | neutral |
| macd_signal | 3.80 | bearish |
| macd_histogram | -1.00 | bearish |
| boll_mid | 157.92 | neutral |
| boll_upper | 166.65 | bearish |
| boll_lower | 149.19 | bullish |
| atr | 4.05 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Trim 25% — downgrade to Underweight
EV: +175+ on next leg of breakout
EMR at $158 represents the wrong price for a good business, with consensus expectations built on unrealized transformation, 64% goodwill concentration, negative tangible book value, and a technically broken chart — creating asymmetric downside risk that favors patient bears over eager bulls.
EV: -11 to -12% (downside to $140.90) over the next quarter if macro picture deteriorates or Q4 guidance disappoints · concedes: EMR is a good business with strong software mix helping gross margins; Q3 FY26 delivered 6% underlying growth; Equinor frame agreement provides existing revenue visibility; Dividend King status provides income floor; Capital return programs exist; AI/data-center TAM expansion opportunity is real if policy risk doesn't materialize
→ vs conservative: Quality compounder virtues (67 years of dividend increases, $2.4B capital return, 144% FCF conversion) are already priced in at 21.9x forward P/E on a 30-60 day tactical horizon
→ vs conservative: Contract wins are bullish catalysts but are already in the tape; trim into strength is the disciplined move, not waiting for the next leg down
→ vs conservative: Selling a quality compounder that has run 79% in three years, broken its breakout, and shows negative momentum divergence is position management, not a mistake
→ vs neutral: A confirmed multi-signal deterioration inside a long-term uptrend is exactly when to act; waiting for 'confirmation at the 50 SMA at 148' means accepting a 7% drawdown with no catalyst
→ vs neutral: Risk-reward is NOT balanced: 5% upside vs 7% downside with momentum leaning bearish is negative convexity dressed up as patience
→ vs neutral: The neutral is treating consolidation as benign digestion when price action (lower highs, failed August breakout, bearish divergences) tells a different story
| vwma | 159.34 | bearish |
Support: 149.19 · 148.29 · 140.9 | Resistance: 165.79 · 166.65
EMR closed at $158.29 (range 155.50–158.70, vol 2,064,446), trading ~12.3% above its 200 SMA of 140.90 with the full bullish stack (10 EMA > 50 SMA > 200 SMA) intact, confirming a multi-timeframe uptrend. RSI at 56.39 is neutral with a mild bearish divergence versus the early-August high of 165.79, while the MACD line at 2.80 sits below its signal at 3.80 with a negative histogram of −1.00, indicating decelerating but not reversed momentum. Price sits just above the middle Bollinger Band at 157.92 but failed to close above the upper band at 166.65, and remains below the VWMA at 159.34 on lighter recent volume, signaling mild distribution/consolidation rather than accumulation. ATR of 4.05 implies ~2.6% daily swing and suggests stops of $6–$8, with resistance at 165.79/166.65 and support at 149.19/148.29/140.90. The rating is HOLD: trend remains intact with no confirmed breakdown or breakout at current levels.
Market Cap
$88.29 B
Enterprise Value
~$99.9 B
TTM Revenue
$18.636 B
TTM Gross Profit
$9.907 B
TTM EBITDA
$6.058 B
TTM Net Income
$2.576 B
TTM EPS
$4.57
Forward EPS
$7.24
P/E (TTM)
34.6×
Forward P/E
21.9×
PEG Ratio
1.81
P/B
4.33×
Dividend Yield
1.43%
Beta
1.235
52-Week High
$166.35
52-Week Low
$122.64
50-Day Avg
$148.47
200-Day Avg
$141.77
ROE
12.8%
ROA
6.9%
Operating Margin
26.9%
Net Margin
13.8%
Debt/Equity
0.68
Current Ratio
0.90
Free Cash Flow (TTM)
$3.706 B
Book Value / Share
$36.54
Gross Margin
53.2%
EBITDA Margin
32.5%
FCF/Net Income Conversion
144%
Net Debt/EBITDA
1.9×
Total Assets
$42.09 B
Total Debt
$14.06 B
Goodwill + Intangibles
$27.11 B
Cash & Equivalents
$1.79 B
Revenue YoY Growth (Q1 FY26)
+2.9%
Revenue 3Y CAGR
~9.3%
Shares Outstanding
561 M
Dividends Paid (FY25)
$1.19 B
Buybacks (FY25)
$1.17 B
Annual Dividend Per Share
$2.11
Strengths
Concerns
EMR is a transformed pure-play industrial automation company with best-in-class 32.5% EBITDA margins and exceptional 144% FCF conversion generating $3.71B in free cash flow. The forward P/E of 21.9× is supported by expected ~58% EPS growth (TTM $4.57 → $7.24) from NI integration synergies and software subscription ramp. Despite strong fundamentals, the HOLD rating reflects balanced risk/reward at current levels near 52-week highs, with the stock trading 20% above its 200-day moving average — warrants holding existing positions and adding on pullbacks toward the $148 50-day MA or $142 200-day MA levels.
Macro: Fed rate cuts in 2026: 87% probability of NO cuts (1-week +1.9pp) — higher-for-longer headwind but EMR's long-duration contracts insulate near-term revenue. US recession by end-2026: 8% probability — tail risk de minimis, industrial cycle likely expanding. WTI crude above $90 in Aug 2026: 4% (1-week −34pp); $95 → 2%; $100 → 1% — oil has rolled over, modest upstream capex risk mitigated by locked-in awards. State data-center moratorium by YE 2026: 68% probability — single most relevant macro variable for EMR's AI thesis.